Yukinori Minoshima

TL;DR: Activity of EPZ-6438 is characterized in preclinical models of NHL to confirm the dependency of EZH2-mutant NHL on EzH2 activity and portend the utility ofEPZ- 6438 as a potential treatment for these genetically defined cancers.

TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.

TL;DR: These sulfonamides represent selective chemical probes for disrupting CAPERα function and designate DCAFs as promising drug targets for promoting selective protein degradation in cancer therapy.

TL;DR: It is shown that pladienolide exerts its potent activity by targeting SF3b and also suggest that inhibition of SF3B is a promising drug target for anticancer therapy.

TL;DR: The results suggest that lenvatinib has antitumor activity consistently across diverse HCC models, and that targeting of tumor FGF signaling pathways and anti‐angiogenic activity underlies its antitUMor activity against HCC tumors.